TWI859506B - 化合物組合用於製作血管疾病治療藥的用途 - Google Patents

化合物組合用於製作血管疾病治療藥的用途 Download PDF

Info

Publication number
TWI859506B
TWI859506B TW111104639A TW111104639A TWI859506B TW I859506 B TWI859506 B TW I859506B TW 111104639 A TW111104639 A TW 111104639A TW 111104639 A TW111104639 A TW 111104639A TW I859506 B TWI859506 B TW I859506B
Authority
TW
Taiwan
Prior art keywords
sildenafil
vascular
compound combination
treatment
sild
Prior art date
Application number
TW111104639A
Other languages
English (en)
Chinese (zh)
Other versions
TW202332450A (zh
Inventor
招名威
林欽鴻
陳伯東
Original Assignee
未來新藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 未來新藥股份有限公司 filed Critical 未來新藥股份有限公司
Priority to TW111104639A priority Critical patent/TWI859506B/zh
Priority to JP2024547249A priority patent/JP2025504219A/ja
Priority to CN202310100652.1A priority patent/CN116808224A/zh
Priority to KR1020247028842A priority patent/KR20240146018A/ko
Priority to EP23706081.9A priority patent/EP4475833A1/en
Priority to PCT/GB2023/050296 priority patent/WO2023152500A1/en
Priority to US18/836,532 priority patent/US20250134892A1/en
Priority to AU2023219232A priority patent/AU2023219232A1/en
Publication of TW202332450A publication Critical patent/TW202332450A/zh
Application granted granted Critical
Publication of TWI859506B publication Critical patent/TWI859506B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW111104639A 2022-02-09 2022-02-09 化合物組合用於製作血管疾病治療藥的用途 TWI859506B (zh)

Priority Applications (8)

Application Number Priority Date Filing Date Title
TW111104639A TWI859506B (zh) 2022-02-09 2022-02-09 化合物組合用於製作血管疾病治療藥的用途
JP2024547249A JP2025504219A (ja) 2022-02-09 2023-02-09 Pde5阻害剤、アルギニン、及びn-アセチルシステインを含む、血管疾患を治療するための化合物の組合せ
CN202310100652.1A CN116808224A (zh) 2022-02-09 2023-02-09 用于治疗血管疾病的化合物组合
KR1020247028842A KR20240146018A (ko) 2022-02-09 2023-02-09 Pde5 억제제, 아르기닌 및 n-아세틸시스테인을 포함하는 혈관 질병 치료를 위한 화합물의 병용
EP23706081.9A EP4475833A1 (en) 2022-02-09 2023-02-09 Combination of compounds for treating vascular diseases comprising pde5 inhibitor, arginine and n-acetylcysteine
PCT/GB2023/050296 WO2023152500A1 (en) 2022-02-09 2023-02-09 Combination of compounds for treating vascular diseases comprising pde5 inhibitor, arginine and n-acetylcysteine
US18/836,532 US20250134892A1 (en) 2022-02-09 2023-02-09 Combination of compounds for treating vascular diseases comprising pde5 inhibitor, arginine and n-acetylcysteine
AU2023219232A AU2023219232A1 (en) 2022-02-09 2023-02-09 Combination of compounds for treating vascular diseases comprising pde5 inhibitor, arginine and n-acetylcysteine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TW111104639A TWI859506B (zh) 2022-02-09 2022-02-09 化合物組合用於製作血管疾病治療藥的用途

Publications (2)

Publication Number Publication Date
TW202332450A TW202332450A (zh) 2023-08-16
TWI859506B true TWI859506B (zh) 2024-10-21

Family

ID=85283927

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111104639A TWI859506B (zh) 2022-02-09 2022-02-09 化合物組合用於製作血管疾病治療藥的用途

Country Status (8)

Country Link
US (1) US20250134892A1 (cg-RX-API-DMAC10.html)
EP (1) EP4475833A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025504219A (cg-RX-API-DMAC10.html)
KR (1) KR20240146018A (cg-RX-API-DMAC10.html)
CN (1) CN116808224A (cg-RX-API-DMAC10.html)
AU (1) AU2023219232A1 (cg-RX-API-DMAC10.html)
TW (1) TWI859506B (cg-RX-API-DMAC10.html)
WO (1) WO2023152500A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI879058B (zh) * 2023-08-31 2025-04-01 未來新藥股份有限公司 Pde5抑制劑組合於促進神經突生長之新穎用途
CN122055146A (zh) * 2023-08-31 2026-05-15 未来新药股份有限公司 Pde5抑制剂组合于促进神经突生长的新颖用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000000212A1 (en) 1998-06-26 2000-01-06 Nutracorp Scientific, Inc. Promoting nitric oxide and cyclic gmp activity

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL132460A0 (en) * 1999-10-19 2001-03-19 Laniado Shlomo Sildenafil preparation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000000212A1 (en) 1998-06-26 2000-01-06 Nutracorp Scientific, Inc. Promoting nitric oxide and cyclic gmp activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 Ruipeng Zhang,et al "N-Acetylcysteine potentiates the haemodynamic-improving effect of sildenafil in a rabbit model of acute pulmonary thromboembolism via the p38 MAPK pathway", Clin Exp Pharmacol Physiol, 46(2): 163-172, 2019 Feb. *

Also Published As

Publication number Publication date
CN116808224A (zh) 2023-09-29
US20250134892A1 (en) 2025-05-01
TW202332450A (zh) 2023-08-16
EP4475833A1 (en) 2024-12-18
KR20240146018A (ko) 2024-10-07
WO2023152500A1 (en) 2023-08-17
AU2023219232A1 (en) 2024-07-25
JP2025504219A (ja) 2025-02-06

Similar Documents

Publication Publication Date Title
Bywaters et al. Crush injuries with impairment of renal function
Schurr et al. Blockade of lactate transport exacerbates delayed neuronal damage in a rat model of cerebral ischemia
Sánchez-Lozada et al. Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia
Mehanna et al. An optimized dose of raspberry ketones controls hyperlipidemia and insulin resistance in male obese rats: Effect on adipose tissue expression of adipocytokines and Aquaporin 7
JP2001526658A (ja) 虚血の治療および/または予防を行う際の医薬組成物の使用
TW202332450A (zh) 化合物組合用於製作血管疾病治療藥的用途
Dinc et al. Methylene blue inhibits the inflammatory process of the acetic acid-induced colitis in rat colonic mucosa
Hanrahan et al. A randomized, placebo‐controlled, multiple‐ascending‐dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of the soluble guanylate cyclase stimulator praliciguat in healthy subjects
Zhang et al. GSK-3β inhibition elicits a neuroprotection by restoring lysosomal dysfunction in neurons via facilitation of TFEB nuclear translocation after ischemic stroke
Sorensen et al. Clinical evaluation of benzbromarone. A new uricosuric drug
Benigni et al. Renoprotection by nitric oxide donor and lisinopril in the remnant kidney model
Hedayati et al. Growth hormone–releasing peptide ghrelin inhibits homocysteine-induced endothelial dysfunction in porcine coronary arteries and human endothelial cells
Moustafa et al. Sildenafil citrate protects against gastric mucosal damage induced by indomethacin in rats.
Mendel et al. Pharmacology management in improving exercise capacity of patients with Fontan circulation: a systematic review and meta-analysis
Kumar et al. Intravenous sildenafil citrate and post-cardiac surgery acute kidney injury: a double-blind, randomised, placebo-controlled trial
Ko et al. Therapeutic hypothermia protects against heat stroke-induced arterial hypotension via promoting left ventricular performance in rats
Liu et al. Protective effect of crocin on liver function and survival in rats with traumatic hemorrhagic shock
JP2020525511A (ja) 低濃度のキセノンおよびアルゴンを含有するガス混合物は血栓溶解剤の触媒活性を阻害することなく神経保護を提供する
GB2600668A (en) Alpha Lipoic Acid (A-ALA) and Alpha Lipoic Acid (R-ALA) As a Pharmaceutical Product for Intravenous Application to reduce Inflammation from infection.
Gruber et al. Protracted metabolic acidosis: the impact of acute ethanol in hemorrhagic shock
Harada et al. Role of neutrophil elastase in development of pulmonary vascular injury and septic shock in rats
Kirkeb⊘ en et al. Importance of nitric oxide in canine femoral circulation: comparison of two NO inhibitors
TWI907160B (zh) 具有護腎功效的咪唑二肽組合物及其應用
Yu et al. Protective Effect of Sufentanil against Myocardial Ischemia Reperfusion Injury in Rats
Liu et al. Cavernosum smooth muscle relaxation induced by Schisandrol A via the NO-cGMP signaling pathway